HomeNews

News

KITE-363 Exhibits Excessive Response in B-Cell Lymphoma With Manageable Security

The twin-targeting CAR T-cell remedy KITE-363 confirmed constructive response charges and manageable unwanted effects in relapsed or refractory B-cell lymphoma.Amongst sufferers with relapsed/refractory...

Sasanlimab-BCG Combo Might Delay Recurrence in Bladder Most cancers

Including subcutaneous sasanlimab to Bacillus Calmette-Guérin (BCG) improved recurrence-free survival in non–muscle-invasive bladder most cancers, in accordance with findings from the CREST trial...

Personalised Vaccine Elicits Responses in Sufferers With Kidney Most cancers

CURE spoke with the principal investigator of a scientific trial evaluating a therapeutic vaccine in superior kidney most cancers: © inventory.adobe.com.Dr. David Braun...

The Invisibility of Blood Cancers to Others

Jane Biehl is a 12-year survivor of a really uncommon type of blood most cancers, generally known as myelodysplastic syndrome (MDS). Atone for all...

MVdeltaC Earns Orphan Drug Standing for Pleural Mesothelioma

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future growth.The U.S. Meals and Drug...

Hot Topics